Sat. October 11, 2008
+
PharmiWeb.com (press release)
October 10, 2008
Lyon, 10th October 2008 - RotaTeq®, the pentavalent rotavirus vaccine from Sanofi Pasteur MSD and Merck & Co. Inc., that helps prevent rotavirus ...
MarketWatch
October 10, 2008
Datamonitor expects JnJ/Tibotec and
Merck to be the fastest growing
companies over the next 10 years. While Tibotec only entered the field with the launch ...
RTT News
October 10, 2008
Merck also added that it has committed to provide additional safety and efficacy data from
Africa and
Asia, and is currently conducting clinical trials in ...
Seeking Alpha
October 10, 2008
In 2005, Hi-Tech Pharmacal (HITK) became the first company to file a paragraph IV certification relating to Merck's (MRK) glaucoma drugs Trusopt and Cosopt. ...
Wall Street Journal Blogs
October 10, 2008
It was only in March of last year that a national experts' committee recommended that teenage girls get vaccinated with Merck's Gardasil, which protects ...
Motley Fool
October 10, 2008
But even here, drug
companies seem to be in a no-win situation -- witness
Merck and Schering-Plough getting flack for releasing some safety-related data ...
Pittsburgh Tribune-Review
October 10, 2008
By Bloomberg News Mylan Inc., the biggest US maker of generic drugs, is "well capitalized" and able to manage debt from last year's purchase of Merck KGaA's ...
Bizjournals.com
October 10, 2008
... partnership between Vanderbilt Kennedy Center and the Vanderbilt Department of Psychiatry. It is funded by a three-year grant from the John Merck Fund.
Los Angeles Times
October 10, 2008
He said data released earlier in the year by Gardasil's manufacturer, Merck & Co., show that only about 1% of Latina teens were receiving the vaccine, ...
Seattle Times
October 10, 2008
The figures represent the government's first substantial study of vaccination rates for Gardasil, Merck's heavily advertised, three-shot series that targets ...
InjuryBoard.com
October 10, 2008
New evidence emerging from the Merck lawsuits over the painkiller Vioxx shows that the company repeatedly lied to both the FDA and respected medical ...
Natural News.com
October 10, 2008
(NaturalNews)
children who take
Merck's combination vaccine ProQuad suffer from convulsions twice as frequently as children who are given two separate ...
Bloomberg
October 10, 2008
By Shannon Pettypiece Oct. 9 (Bloomberg) --
Merck & Co.'s
cervical cancer vaccine Gardasil was given to a quarter of teenage girls last year after a $100 ...
CBS 3
October 9, 2008
Even though
Merck, the drug's manufacturer, recently added depression and suicidal thoughts to the list of less common side effects, their
parents say ...
PR-Inside.com (Pressemitteilung)
October 9, 2008
EMD Chemicals is a
United States subsidiary of
Merck KGaA in Darmstadt,
Germany. KGaA's materials. After successfully meeting initial development milestones ...
Chatter Shmatter
October 8, 2008
Results of a new study find that a drug from Merck called Proscar, which is used to control a man's enlarged prostate, does not increase the risk of hip ...
Hays Pharma
October 8, 2008
Merck has announced that researchers are to conduct a clinical trial of its
HIV treatment raltegravir. The medicine will be assessed as a once-daily dose in ...
Mass High Tech
October 8, 2008
By Mass High Tech Staff Nanotechnology firm Nano-Terra Inc. and German drug maker Merck KGaA have upgraded their product development partnership to a ...
Boston Globe
October 8, 2008
EMD Chemicals Inc.,
the US division of
Merck KGaA of
Germany, said today it is extending its existing alliance with Nano-Terra Inc., a Cambridge start-up ...
Chicago Tribune
October 8, 2008
After Lilly's announcement, Merck & Co. said it would also begin disclosing payments to doctors, starting next year. Those are welcome steps, presuming the ...
New York Times
October 8, 2008
In April, for example, a group of academic doctors questioned the validity of drug industry research after finding that
Merck had hired
ghostwriters to ...
Bloomberg
October 8, 2008
Chitsulo was accompanied by representatives from Merck KGaA, which makes praziquantel, the most effective medicine against schistosomiasis. ...
Bizjournals.com
October 7, 2008
The second-largest was the $58 million May agreement reached with
Merck & Co. (
nyse:MRK) over Vioxx, a settlement that netted
Ohio $2.84 million. ...
Earthtimes (press release)
October 7, 2008
In connection with the financing, Alan Sachs , MD, Ph.D., Vice President of RNA Therapeutics for Merck Research Laboratories, was elected to the Odyssey ...
New York Times
October 7, 2008
It is the largest settlement paid by a drug company in a state consumer protection case, topping the $58 million that Merck paid to settle similar ...
Newsinferno.com
October 6, 2008
Now, due to a lawsuit over the injuries caused by Merck's painkiller Vioxx, Merck has been forced to unseal documents over its initial research on Vioxx ...
CNNMoney.com
October 6, 2008
Lilly Chief Executive John Lechleiter told analysts he looked forward to working with Bristol-Myers, which
markets Erbitux in
the US and
Canada , and
Merck ...
Imperial Valley News
October 6, 2008
The challenge was that the pricey system Merck Research Labs originally invested in proved to be labor-intensive and convoluted, needing its own cadre of ...
Seeking Alpha
October 5, 2008
If you're going to look out more than a year or two, you'd have a tough time convincing anyone that
Merck,
Pfizer, J&J and Bristol Myers are all going out ...
eFluxMedia
October 5, 2008
By Dianna Cooper Merck & Co. has decided to bring to an end the development the experimental obesity drug taranabant on account of its many adverse events, ...
The News-Press
October 5, 2008
Traiger said he expects he'll be able to vaccinate his patients once Merck, the drug's manufacturer, catches up with the orders. Traiger is waiting for his ...
Newsinferno.com
October 4, 2008
Since the FDA began its investigation, Merck, the drug's manufacturer, says it has been "informing doctors and patients of this new information in several ...
Forbes
October 3, 2008
Medical News Today (press release)
October 3, 2008
Motley Fool
October 3, 2008
By Brian Orelli After lackluster results in a phase 3 trial,
Merck (
nyse: MRK) has decided that it's just not very high on its anti-obesity compound anymore ...
CNW Telbec (Communiqués de presse)
October 3, 2008
Discovered and developed by Merck, aprepitant is the first in a new class of medicines (neurokinin-1 (NK1) receptor antagonist), indicated in combination ...
PharmiWeb.com (press release)
October 3, 2008
... over a cisplatinum-based chemotherapy and across all histological subtypes," said Dr Wolfgang Wein, Executive Vice President, Oncology, Merck Serono. ...
CNNMoney.com
October 2, 2008
NEW YORK (Associated Press) - Merck & Co. said Thursday it will end a late-stage development program on its potential obesity drug taranabant and abandon ...
Motley Fool
October 2, 2008
Bristol-Myers Squibb (
nyse: BMY) sells it in
the US and
Canada and pays ImClone a 39%
royalty rate, and
Merck KGaA has the rights elsewhere with a 9.5% ...
CNNMoney.com
October 2, 2008
By Peter Loftus Merck & Co. (MRK) took a gamble with an experimental anti-obesity drug, and it didn't pay off. The drug giant Thursday said it halted ...
